DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders
Metadata
Show full item recordEditorial
FRONTIERS MEDIA SA
Materia
Attenuated Psychosis Syndrome (APS) Adolescence Epidemiology Risk Psychosis Prevention
Date
2020Referencia bibliográfica
Salazar de Pablo G, Guinart D, Cornblatt BA, Auther AM, Carrión RE, Carbon M, Jiménez-Fernández S, Vernal DL, Walitza S, Gerstenberg M, Saba R, Lo Cascio N, Brandizzi M, Arango C, Moreno C, Van Meter A, Fusar-Poli P and Correll CU (2020) DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. Front. Psychiatry 11:568982. doi: 10.3389/fpsyt.2020.568982
Sponsorship
John and Maxine Bendheim Foundation; Alicia Koplowitz Foundation; Spanish Government; ERDF Funds from the European Commission, A way of making Europe, CIBERSAM PI17/02227; Madrid Regional Government B2017/BMD-3740 AGES-CM-2; European Union (EU) FP7-4-HEALTH-2009-2.2.1-2-241909 FP7-HEALTH-2013-2.2.1-2-603196 FP7-HEALTH-2013-2.2.1-2-602478; European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking 115916 777394; Fundacion Familia Alonso; Instituto de Salud Carlos IIIAbstract
Introduction: Although attenuated psychotic symptoms often occur for the first time
during adolescence, studies focusing on adolescents are scarce. Attenuated psychotic
symptoms form the criteria to identify individuals at increased clinical risk of developing
psychosis. The study of individuals with these symptoms has led to the release of
the DSM-5 diagnosis of Attenuated Psychosis Syndrome (APS) as a condition for
further research. We aimed to characterize and compare hospitalized adolescents with
DSM-5-APS diagnosis vs. hospitalized adolescents without a DSM-5-APS diagnosis.
Methods: Interviewing help-seeking, hospitalized adolescents (aged 12–18 years) and
their caregivers independently with established research instruments, we (1) evaluated
the presence of APS among non-psychotic adolescents, (2) characterized and compared
APS and non-APS individuals regarding sociodemographic, illness and intervention
characteristics, (3) correlated psychopathology with levels of functioning and severity of
illness and (4) investigated the influence of individual clinical, functional and comorbidity
variables on the likelihood of participants to be diagnosed with APS.
Results: Among 248 consecutively recruited adolescents (age=15.4 ± 1.5 years,
females = 69.6%) with non-psychotic psychiatric disorders, 65 (26.2%) fulfilled APS
criteria and 183 (73.8%) did not fulfill them. Adolescents with APS had higher number of psychiatric disorders than non-APS adolescents (3.5 vs. 2.4, p < 0.001; Cohen’s
d = 0.77), particularly, disruptive behavior disorders (Cramer’s V = 0.16), personality
disorder traits (Cramer’s V = 0.26), anxiety disorders (Cramer’s V = 0.15), and eating
disorders (Cramer’s V = 0.16). Adolescents with APS scored higher on positive (Cohen’s
d = 1.5), negative (Cohen’s d = 0.55), disorganized (Cohen’s d = 0.51), and general
symptoms (Cohen’s d = 0.84), and were more severely ill (Cohen’s d = 1.0) and
functionally impaired (Cohen’s d = 0.31). Negative symptoms were associated with lower
functional levels (Pearson ρ = −0.17 to −0.20; p = 0.014 to 0.031). Global illness
severity was associated with higher positive, negative, and general symptoms (Pearson
ρ = 0.22 to 0.46; p = 0.04 to p < 0.001). APS status was independently associated
with perceptual abnormalities (OR = 2.0; 95% CI = 1.6–2.5, p < 0.001), number of
psychiatric diagnoses (OR = 1.5; 95% CI = 1.2–2.0, p = 0.002), and impaired stress
tolerance (OR = 1.4; 95% CI = 1.1–1.7, p = 0.002) (r
2 = 0.315, p < 0.001).
Conclusions: A considerable number of adolescents hospitalized with non-psychotic
psychiatric disorders meet DSM-5-APS criteria. These help-seeking adolescents have
more comorbid disorders and more severe symptoms, functional impairment, and
severity of illness than non-APS adolescents. Thus, they warrant high intensity
clinical care.